menu
    • menu

    Company profile for Vivacelle Bio

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vivacelle restores blood pressure, circulating volume and there by increases survival in animal models of hypovolemia. Hypovolemia, which occurs when there is inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Causes include acute blood loss from trauma, surgery, shock, sepsis, severe diarrhea and burns. When the circulating volume is inadequate to maintain tissue p...
    Vivacelle restores blood pressure, circulating volume and there by increases survival in animal models of hypovolemia. Hypovolemia, which occurs when there is inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Causes include acute blood loss from trauma, surgery, shock, sepsis, severe diarrhea and burns. When the circulating volume is inadequate to maintain tissue perfusion and oxygenation, cellular injury and death may result. Provides an energy source. The Company’s first product, Vivacelle, is a soybean oil based colloid volume expander that has been shown to be safer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vivacelle BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Northeast Indiana Innovation Center, 3201 Stellhorn Road Suite 129 A
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vivacellebio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vivacelle-bio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vivacelle Bio Commemorates Sepsis Awareness Month in U.S. Hospitals
    Vivacelle Bio Commemorates Sepsis Awareness Month in U.S. Hospitals

    24 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vivacelle-bio-commemorates-sepsis-awareness-month-recognizing-the-leading-cause-of-death-in-us-hospitals-302255761.html

    PR NEWSWIRE
    24 Sep 2024
    Share Share
    Vivacelle Bio’s VBI-S PhIIa Trial Meets Primary and Secondary Endpoints
    Vivacelle Bio’s VBI-S PhIIa Trial Meets Primary and Secondary Endpoints

    09 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230209005014/en/Vivacelle-Bio%E2%80%99s-VBI-S-Phase-IIa-Clinical-Trial-Meets-Primary-and-Secondary-Endpoints-for-Treating-Hypovolemia-in-Septic-Shock-Patients

    BUSINESSWIRE
    09 Feb 2023
    Share Share
    Vivacelle Bio Announces Results of Phase IIa Trial of VBI-S
    Vivacelle Bio Announces Results of Phase IIa Trial of VBI-S

    20 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221020005031/en

    BUSINESSWIRE
    20 Oct 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search